|
Jun 15, 2022
Coya Therapeutics Secures Option Agreement for Exclusive Worldwide Rights to Exosome Engineering Technology from Carnegie Mellon University
|
|
|
Jun 07, 2022
Coya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Regulatory T cell Therapeutics
|
|
|
Apr 27, 2022
Coya Therapeutics Announces Annals of Neurology Publication Featuring Biomarker Data in ALS Patients Treated with Tregs Cell Therapy
|
|
|
Apr 22, 2022
Coya Therapeutics to Participate in B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
|
|
|
Dec 10, 2021
Coya Therapeutics Applauds U.S. House of Representatives for Passing ACT for ALS
|
|
|
Nov 16, 2021
Coya Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA on COYA101 for the Treatment of Amyotrophic Lateral Sclerosis
|
|
|
Nov 01, 2021
Coya Therapeutics Appoints Dr. Adrian Hepner as Chief Medical Officer and Dr. Greg MacMichael as Chief Technical Officer
|
|
|
Jul 14, 2021
Coya Therapeutics to Participate at the LifeSci Partners Summer Symposium
|
|
|
Jul 07, 2021
Coya Therapeutics Receives Orphan Drug Designation from the FDA for ALS001, an Autologous Treg Cell Therapy, for the Treatment of ALS
|
|
|
Jun 02, 2021
Coya Therapeutics to Host Key Opinion Leader Webinar on ALS001 for the Treatment of Amyotrophic Lateral Sclerosis
|
|
|
Jun 01, 2021
Ann Lee, Ph.D., SVP at Bristol Myers Squibb, Joins Coya Therapeutics™ Board of Directors
|
|
|
May 25, 2021
Coya Therapeutics™ Announces the Appointment of Anabella Villalobos, Ph.D. to its Board of Directors
|
|
|
Apr 14, 2021
Coya Therapeutics™ Announces the Appointment of Hideki Garren, M.D., Ph.D., and Dov Goldstein, M.D., to Its Board of Directors
|
|
|
Feb 23, 2021
Coya Therapeutics™ Announces Formation of Scientific Advisory Board
|
|